Navigation Links
Simcere Pharmaceutical Group Announces Collaboration with OSI Pharmaceuticals
Date:10/20/2009

NANJING, China, Oct. 20 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR) ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

Headquartered in Long Island, OSI is a NASDAQ listed pharmaceutical company specialized in discovery and development of innovative molecular targeted therapies. OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in tumor models representative of small cell lung cancer, glioblastoma, colorectal, renal, head and neck, non-small cell lung cancer and gastric cancers. The company completed a phase I dose escalation study of OSI-930 in healthy volunteers. A phase I single agent dose escalation study in cancer patients has identified a recommended phase II dose and a phase Ib dose escalation study with erlotinib has also identified a recommended dose for the combination. Both phase I studies in cancer patients have been reported at recent ASCO meetings.

"OSI-930 has potential to help cancer patients, and we are delighted to cooperate with OSI Pharmaceuticals to promote this treatment in China," commented Mr. Jinsheng Ren, Chairman and Chief Executive Officer of Simcere Pharmaceutical Group. "We believe that this is a groundbreaking agreement which will become a model for future R&D cooperation between Chinese and foreign pharmaceutical companies."

'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014   Taiho ... Co., Ltd. ( Japan ), announced ... granted Fast Track designation for TAS-102 (nonproprietary names: ... drug under investigation for the treatment of refractory ... has initiated a rolling NDA submission to the ...
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014  BioPontis Alliance ... (HNF), both philanthropies, announced today the creation of ... the treatment of the rare disease known as ... announced its alliance model earlier this month. Today,s ... of a collaborative model where researchers and all ...
(Date:10/18/2014)... , Oct. 18, 2014  In a ... Rights Campaign (HRC), the nation,s largest lesbian, gay, ... endorsed the use of Truvada for Pre-Exposure Prophylaxis ... tool used to prevent the spread of a ... the only brand name anti-HIV drug combination currently ...
Breaking Medicine Technology:Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3
... announces that a new market research report is ... Global Overview of Herbal/Traditional Products ... for "safer and natural" options remains strong in ... of traditional medicine, consumers are increasing their purchases ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), today announced ... preferred Tier 2 formulary status with CVS Caremark ... and Part D Drug Lists), two of the ... million Americans.(1) The U.S. Food and Drug Administration ...
Cached Medicine Technology:Reportlinker Adds A Global Overview of Herbal/Traditional Products 2Pradaxa Gains Preferred Formulary Status with Key Pharmacy Benefit Managers 2Pradaxa Gains Preferred Formulary Status with Key Pharmacy Benefit Managers 3Pradaxa Gains Preferred Formulary Status with Key Pharmacy Benefit Managers 4Pradaxa Gains Preferred Formulary Status with Key Pharmacy Benefit Managers 5
(Date:10/20/2014)... 2014 Succeed is proud to announce that ... participated in the Every Body Walk! campaign by ... project that encourages workers to be more active outside of ... which concluded at the end of September, was a friendly ... metro areas. Participating companies gave their staff pedometers and ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Silver Spring, Maryland, USA (PRWEB) October 20, 2014 ... readers or to track interventions? Here comes a wonderful ... leading mobile app development company helped its ... track Intervention more efficiently. The app is designed for ... iPad, and iPod touch. This app is optimized for ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many ... latest designs of 2014 mother of the bride ... are offered with big discounts, up to 70% off. ... can enjoy this special offer. , Owing to ... become one of the leading brands in the global ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... of about 20% of the women who have attained the childbearing ... across the US involving several thousand women. //In the case of ... women belonging to the 16 years to 49 years age group, ... ,The Illinois Chapter of the Sierra Club’s Jack Darin has termed ...
... manufacturer of the experimental AIDS drug GS 9137 Gilead Sciences ... were successful, as lower levels of HIV were noticed in ... The experiment was conducted over a period of 10 days ... were also not seen to be of a serious nature. ...
... Agency for Healthcare Research and Quality has reported that more ... treat burn victims is billed to Medicare or Medicaid, government ... ,According to statistics, the average charge is $59,600 ... the average charge for burn victims with private insurance ...
... :When you doodle for a cause, then it is art ... rub shoulders with the Who’s Who clan, to name a ... their mite for the third National Doodle Day on March ... for the Epilepsy Action and The Neurofibromatosis Association, and is ...
... lives in a competitive world, according to a recent ... educational achievements are concerned, // there is not much ... with a normal birth weight. Earlier research suggested premature ... and academic achievement. ,The researchers studied ...
... following use of the drug aprotinin, marketed as Trasylol, ... drug in heart surgery patients.// The clotting drug is ... cardiac surgery. ,It has now been found ... twice as likely to develop kidney failure and suffer ...
Cached Medicine News:Health News:Art Attack: Doodling For a Cause! 2Health News:Safety Of Heart Drug Questioned 2
SAFE-T-VAC Coil Packed Suction Catheters Kits, Sterile without Solution...
Sterile, Coil Packed Suction Catheter Mini Tray with (2) Walleted SAFESKIN PURPLE NITRILE Latex-Free Exam Gloves...
Clear plastic sleeve envelopes a plastic suction catheter. Sleeve slides over exudate to reduce potential clinician contact....
Soft and flexible whistle tip catheter with 2 eye configuration. "Chimney" connector with standard tapered fit and thumb control. Available in sizes 6 18 French. Packaged straight....
Medicine Products: